Valeris Emerges as a Key Player in Life Sciences with Integrated Solutions

On May 27, 2025, Valeris was officially launched following the completion of the merger between two significant players in the life sciences field, Mercalis and PharmaCord. With this strategic merger, Valeris aims to provide a comprehensive suite of services tailored to meet the challenges of today's complex healthcare landscape.

A New Beginning

The rebranding reflects a unification of capabilities and expertise, creating a robust platform for life sciences companies dedicated to enhancing patient experiences. The merger leveraged the strengths of both companies, combining Mercalis's advanced commercialization skills with PharmaCord's patient service solutions.

Valeris has positioned itself as a leader in the biopharmaceutical sector, focusing on improving how innovative therapies are brought to patients. Backed by significant investment from global firms Permira and Odyssey Investment Partners, Valeris intends to redefine the scope and quality of patient support services in the industry.

Understanding Valeris's Vision

Rob Truckenmiller, CEO of Valeris, emphasizes the need for a shift in patient support models. He notes, “To remain effective and relevant, patient support must evolve, shifting from commoditized models to dynamic, data-driven ecosystems designed for long-term value.” This underscores Valeris's commitment to cultivating a patient-centric approach that streamlines access and ensures adherence to prescribed therapies.

As part of its offerings, Valeris will focus on data analytics, patient engagement tools, and strategic insights that empower life sciences companies to navigate the complexities of healthcare with confidence. The goal is to enhance not only the experience of healthcare providers but also that of the patients who depend on these life-saving therapies.

The Comprehensive Service Offering

Valeris is more than just a name change; it's a transformation aimed at creating a seamless experience from diagnosis to treatment. By integrating various services, Valeris can support over 500 life sciences customers and facilitate access and affordability for millions of patients.

With more than 33 years of combined industry experience, the leadership team at Valeris is dedicated to making the journeys of patients and healthcare providers smoother than ever before. Scott Dulitz, President of Valeris, highlights this commitment as a foundation for future growth: “This brand marks more than a name change – it signals our commitment to leading progress in healthcare.”

Future Impact on Life Sciences

As the healthcare environment continues to evolve, Valeris emerges not just as a partner but as a catalyst for change in how therapies are delivered. The reimagined company seeks to tackle barriers to patient access while delivering strategic insights to health providers and improving overall patient outcomes.

In summary, Valeris stands ready to lead the charge in life sciences, ensuring that therapy access is no longer a challenge for patients but a seamless part of their healthcare journey. The merger of Mercalis and PharmaCord represents a strategic alliance that promises innovative solutions that will shape the future of the biopharmaceutical landscape.

Conclusion

As Valeris embarks on its mission to enhance patient care through an integrated approach to life sciences, the focus remains firmly on driving progress and improving lives. For additional information, stakeholders and interested parties are encouraged to visit Valeris's website, where further details on their services and philosophy are available.